In vitro evaluation of S-25930 and S-25932, two new quinolones, against aerobic gram-negative isolates from cancer patients.
The in vitro activity of S-25930 and S-25932, two new 4-quinolones, against 450 aerobic gram-negative organisms isolated from cancer patients was evaluated and compared with the activity of ciprofloxacin, enoxacin, difloxacin (A-56619), and A-56620. Both agents inhibited most members of the family Enterobacteriaceae at concentrations of less than or equal to 2.0 micrograms/ml, but their activity against Pseudomonas aeruginosa was inferior to that of other quinolones. Although considerably less active than ciprofloxacin and A-56620, S-25930 was frequently two- to eightfold more active than S-25932 and was comparable to difloxacin and enoxacin against most isolates.
Rolston
K V
KV
Ho
D H
DH
LeBlanc
B
B
Bodey
G P
GP
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D001424:Bacterial Infections / Q000150:complications / Q000382:microbiology; D002939:Ciprofloxacin / Q000031:analogs & derivatives / Q000494:pharmacology; D015365:Enoxacin; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006801:Humans; D009287:Naphthyridines / Q000494:pharmacology; D009369:Neoplasms / Q000150:complications; D011807:Quinolizines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D009287:Naphthyridines; D011807:Quinolizines; D015365:Enoxacin; C049886:ibafloxacin; D002939:Ciprofloxacin; C047225:difloxacin; C049887:S 25932; C047224:sarafloxacin